AR053303A1 - Derivados de 4-fenil-pirimidina-2-carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina k y catepsina s - Google Patents
Derivados de 4-fenil-pirimidina-2-carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina k y catepsina sInfo
- Publication number
- AR053303A1 AR053303A1 ARP050102347A ARP050102347A AR053303A1 AR 053303 A1 AR053303 A1 AR 053303A1 AR P050102347 A ARP050102347 A AR P050102347A AR P050102347 A ARP050102347 A AR P050102347A AR 053303 A1 AR053303 A1 AR 053303A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- halogens
- heterocyclic ring
- membered saturated
- Prior art date
Links
- FNZVQVCHJNEFIQ-UHFFFAOYSA-N 4-phenylpyrimidine-2-carbonitrile Chemical class N#CC1=NC=CC(C=2C=CC=CC=2)=N1 FNZVQVCHJNEFIQ-UHFFFAOYSA-N 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 125000005842 heteroatom Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000006237 oxymethylenoxy group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a derivados de 4-fenil-pirimidina-2-carbonitrilo que tienen la formula general (1) donde R representa 1-3 sustituyentes opcionales seleccionados independientemente entre (C1-6) alquilo (opcionalmente sustituido con uno o más halogenos), (C1-6) alquiloxi (opcionalmente sustituido con uno o más halogenos), ciano, halogeno, hidroxi, nitro, C3-6 cicloalquilo, CO(C1-6)alquilo, S(C1-6)alquilo, SO(C1-6)alquilo, SO2(C1-6)alquilo, SO2NH(C1-8)alquilo, SO2NH2, NHCO(C1-8)alquilo y CO2H; o 2 sustituyentes R en posiciones adyacentes representan juntos OCH2O, OCH2CH2O o CH2CH2O; R1 es H o (C1-6)alquilo; R2 es (C2-6)alquilo, opcionalmente sustituido con OH, (C1-4) alquiloxi, (C6-10) ariloxi, (C6-10)aril(C1-4)-alquiloxi, uno o más halogenos, NR3R4, CO2H o CONR6R7; R3 y R4 son independientemente H, (C1-8)alquilo (opcionalmente sustituido con uno o más halogenos, (C1-4) alquiloxi o (C6-10)-ariloxi), (C3-8) cicloalquilo (opcionalmente sustituido con uno o más halogenos), (C1-4) alquilo sustituido con un anillo heterocíclico saturado de 4-8 miembros que comprende un heteroátomo seleccionado entre O, S y NR5, un anillo heterocíclico saturado de 4-8 miembros que comprende un heteroátomo seleccionado entre O, S y NR5, (C6-10) arilo, (C2-9) heteroarilo (opcionalmente sustituido con uno 1-3 sustituyentes seleccionados entre halogeno, CF3, (C1-4) alquilo y (C1-4) alquiloxi), (C6-10)aril(C1-4) alquilo o (C2-9) heteroaril(C1-4) alquilo; o R3 y R4 junto con el N al cual están unidos, forman un anillo heterocíclico saturado de 4-8 miembros, opcionalmente sustituido con uno o más halogenos o con CONR8R9, y que opcionalmente además comprende uno más heteroátomos seleccionados entre O, S y NR5; o R3 es H o (1-4)-alquilo; y R4 es (C1-4) alquilo sustituido con CONR8R9, COOR10, NR8R9, NR8COR9 o NR8CONR9R10; R5 es H, (C1-4) alquilo (opcionalmente sustituido con (C3-8) cicloalquilo, (C6-10) arilo o (C2-5) heteroarilo), (C3-8) cicloalquilo, (C6-10) arilo o (C2-5)- heteroarilo; R6 y R7 son independientemente H, (C1-4) alquilo o un anillo heterocíclico saturado de 4-8 miembros que comprende un heteroátomo seleccionado entre O, S y NR5; o R6 y R7, junto con el N al cual están unidos, forman un anillo heterocíclico saturado de 4-8 miembros, opcionalmente sustituido con uno o más halogenos, y que opcionalmente además comprende uno o más heteroátomos seleccionados entre O, S y NR5; R8 y R9 son independientemente h o (C1-4) alquilo, o R8 y R9, junto con los átomos con los cuales están unidos, forman un anillo heterocíclico saturado de 4-8 miembros, que opcionalmente comprende uno o mas heteroátomos seleccionados entre O, S y NR5; R10 es H o (C1-4) alquilo; o una sal farmacéuticamente aceptable de los mismos. Se refiere también a composiciones farmacéuticas que comprenden dichos derivados, y también al uso de los mismos en el tratamiento de osteoporosis, ateroesclerosis, inflamacion y trastornos inmunes tal como artritis reumatoide, y dolor cronico tal como dolor neuropático.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04253491 | 2004-06-11 | ||
| EP04106949 | 2004-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053303A1 true AR053303A1 (es) | 2007-05-02 |
Family
ID=34972893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102347A AR053303A1 (es) | 2004-06-11 | 2005-06-09 | Derivados de 4-fenil-pirimidina-2-carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina k y catepsina s |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7589095B2 (es) |
| EP (1) | EP1758870B1 (es) |
| JP (1) | JP2008501764A (es) |
| KR (1) | KR20070043779A (es) |
| CN (1) | CN1980897A (es) |
| AR (1) | AR053303A1 (es) |
| AT (1) | ATE404542T1 (es) |
| AU (1) | AU2005251923A1 (es) |
| BR (1) | BRPI0511951A (es) |
| CA (1) | CA2567845A1 (es) |
| DE (1) | DE602005008960D1 (es) |
| DK (1) | DK1758870T3 (es) |
| EC (1) | ECSP067074A (es) |
| ES (1) | ES2313380T3 (es) |
| IL (1) | IL179444A0 (es) |
| MX (1) | MXPA06014423A (es) |
| MY (1) | MY140123A (es) |
| NO (1) | NO20070146L (es) |
| NZ (1) | NZ551772A (es) |
| PE (1) | PE20060432A1 (es) |
| PL (1) | PL1758870T3 (es) |
| PT (1) | PT1758870E (es) |
| RS (1) | RS20060662A (es) |
| RU (1) | RU2382773C2 (es) |
| TW (1) | TW200614993A (es) |
| WO (1) | WO2005121106A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1901747A2 (en) * | 2005-05-25 | 2008-03-26 | Ingenium Pharmaceuticals AG | Pyrimidine-based cdk inhibitors for treating pain |
| CN101528039A (zh) | 2006-05-26 | 2009-09-09 | 路易斯维尔大学研究基金会公司 | 巨噬细胞迁移抑制因子拮抗剂及其应用方法 |
| US8507498B2 (en) | 2007-04-24 | 2013-08-13 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| KR100936278B1 (ko) * | 2007-12-14 | 2010-01-13 | 한국생명공학연구원 | 단백질 포스파타제의 활성을 억제하는 피리미딘 유도체또는 이의 약학적으로 허용가능한 염을 유효성분으로함유하는 암 예방 및 치료용 조성물 |
| US8420653B2 (en) * | 2008-02-01 | 2013-04-16 | Orchid Chemicals & Pharmaceuticals Limited | Pyrimidine compounds and their uses |
| US9162987B2 (en) | 2009-09-24 | 2015-10-20 | University Of Louisville Research Foundation, Inc. | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions |
| US9155790B2 (en) | 2010-05-20 | 2015-10-13 | University of Lousiville Research Foundation, Inc. | Methods and compositions for modulating ocular damage |
| US9314026B2 (en) | 2011-10-06 | 2016-04-19 | Bayer Intellectual Property Gmbh | Heterocyclylpyri(mi)dinylpyrazole |
| US9328118B2 (en) * | 2012-04-17 | 2016-05-03 | Astellas Pharma Inc. | Nitrogen-containing bicyclic aromatic heterocyclic compound |
| CN104211645B (zh) * | 2014-08-12 | 2016-08-24 | 武汉珈瑜科技有限公司 | 嘧啶类衍生物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO890521L (no) * | 1988-02-25 | 1989-08-28 | Bayer Ag | Substituerte pyrimidiner. |
| ATE472535T1 (de) * | 2001-02-14 | 2010-07-15 | Warner Lambert Co | Pyrimidinmatrixmetalloproteinaseinhibitoren |
| US20030144234A1 (en) | 2001-08-30 | 2003-07-31 | Buxton Francis Paul | Methods for the treatment of chronic pain and compositions therefor |
| GB0121033D0 (en) | 2001-08-30 | 2001-10-24 | Novartis Ag | Organic compounds |
| AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201976D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| GB0220187D0 (en) * | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
| US7326715B2 (en) * | 2005-09-23 | 2008-02-05 | N.V. Organon | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
-
2005
- 2005-05-12 TW TW094115416A patent/TW200614993A/zh unknown
- 2005-05-17 MY MYPI20052213A patent/MY140123A/en unknown
- 2005-06-09 EP EP05763140A patent/EP1758870B1/en not_active Expired - Lifetime
- 2005-06-09 BR BRPI0511951-0A patent/BRPI0511951A/pt not_active IP Right Cessation
- 2005-06-09 CN CNA2005800228549A patent/CN1980897A/zh active Pending
- 2005-06-09 JP JP2007526313A patent/JP2008501764A/ja active Pending
- 2005-06-09 US US11/628,623 patent/US7589095B2/en not_active Expired - Fee Related
- 2005-06-09 PE PE2005000659A patent/PE20060432A1/es not_active Application Discontinuation
- 2005-06-09 AR ARP050102347A patent/AR053303A1/es unknown
- 2005-06-09 RU RU2007101161/04A patent/RU2382773C2/ru not_active IP Right Cessation
- 2005-06-09 DK DK05763140T patent/DK1758870T3/da active
- 2005-06-09 NZ NZ551772A patent/NZ551772A/en unknown
- 2005-06-09 WO PCT/EP2005/006266 patent/WO2005121106A1/en not_active Ceased
- 2005-06-09 ES ES05763140T patent/ES2313380T3/es not_active Expired - Lifetime
- 2005-06-09 PL PL05763140T patent/PL1758870T3/pl unknown
- 2005-06-09 RS RSP-2006/0662A patent/RS20060662A/sr unknown
- 2005-06-09 DE DE602005008960T patent/DE602005008960D1/de not_active Expired - Fee Related
- 2005-06-09 KR KR1020077000640A patent/KR20070043779A/ko not_active Withdrawn
- 2005-06-09 MX MXPA06014423A patent/MXPA06014423A/es active IP Right Grant
- 2005-06-09 PT PT05763140T patent/PT1758870E/pt unknown
- 2005-06-09 CA CA002567845A patent/CA2567845A1/en not_active Abandoned
- 2005-06-09 AU AU2005251923A patent/AU2005251923A1/en not_active Abandoned
- 2005-06-09 AT AT05763140T patent/ATE404542T1/de not_active IP Right Cessation
-
2006
- 2006-11-21 IL IL179444A patent/IL179444A0/en unknown
- 2006-12-11 EC EC2006007074A patent/ECSP067074A/es unknown
-
2007
- 2007-01-09 NO NO20070146A patent/NO20070146L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PT1758870E (pt) | 2008-10-15 |
| AU2005251923A1 (en) | 2005-12-22 |
| TW200614993A (en) | 2006-05-16 |
| ATE404542T1 (de) | 2008-08-15 |
| MXPA06014423A (es) | 2007-02-19 |
| PE20060432A1 (es) | 2006-06-23 |
| CN1980897A (zh) | 2007-06-13 |
| ES2313380T3 (es) | 2009-03-01 |
| RS20060662A (sr) | 2008-09-29 |
| HK1100002A1 (en) | 2007-08-31 |
| DK1758870T3 (da) | 2008-10-20 |
| PL1758870T3 (pl) | 2009-01-30 |
| JP2008501764A (ja) | 2008-01-24 |
| NZ551772A (en) | 2009-05-31 |
| BRPI0511951A (pt) | 2008-01-29 |
| ECSP067074A (es) | 2007-01-26 |
| EP1758870B1 (en) | 2008-08-13 |
| EP1758870A1 (en) | 2007-03-07 |
| DE602005008960D1 (de) | 2008-09-25 |
| CA2567845A1 (en) | 2005-12-22 |
| WO2005121106A1 (en) | 2005-12-22 |
| US20080090813A1 (en) | 2008-04-17 |
| NO20070146L (no) | 2007-02-02 |
| RU2007101161A (ru) | 2008-07-20 |
| IL179444A0 (en) | 2007-05-15 |
| MY140123A (en) | 2009-11-30 |
| US7589095B2 (en) | 2009-09-15 |
| RU2382773C2 (ru) | 2010-02-27 |
| KR20070043779A (ko) | 2007-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123089A2 (es) | Compuesto de piridinona | |
| AR083543A1 (es) | Diamidas de amino-pirrolidin-azetidinas, composiciones farmaceuticas que las contienen y uso de las mismas para tratar dolores inflamatorios | |
| AR053303A1 (es) | Derivados de 4-fenil-pirimidina-2-carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina k y catepsina s | |
| AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| AR078776A1 (es) | Derivados de (1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)-fenilo | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
| AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| AR068840A1 (es) | Moduladores del gpr40 bifenilo sustituidos y composiciones farmaceuticas que los contienen | |
| AR043998A1 (es) | Acidos fenoxiaceticos | |
| EA201201052A1 (ru) | Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk | |
| CO6150164A2 (es) | Derivados de 2-metilmorfolina pirido-,pirazo-ypirimido-pirimidina como inhibidores de mtor | |
| CO6160230A2 (es) | Arilsulfonamidas con efecto analgesico | |
| AR079231A1 (es) | Derivados de imidazoquinolina | |
| PE20171240A1 (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| AR089285A1 (es) | Derivados de betulina | |
| PE20210398A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados | |
| AR047682A1 (es) | Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR041170A1 (es) | Derivados de bencimidazol, benzoxazol y benzotiazol | |
| AR082633A1 (es) | Analogos de tetraciclina | |
| AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |